Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Diabetes

Patients and Families Make Emotional Plea at Senate Hearing for Diabetes Research Funding

Washington, DC, July 27, 2017 — Summer Park reports on Roll Call that families and advocates delivered an emotional plea for more diabetes research funding before Congress on July 26.

People with type 1 diabetes, including over 160 children, were on hand for a hearing before the Senate Special Committee on Aging.

Those testifying urged lawmakers to extend the Special Diabetes Program, which funds research into type 1 diabetes.  The program will run out of funds this September if lawmakers don’t act. Continue reading

PhRMA Report: 170+ Medicines in Development for Diabetes that Offer Patients Longer, Healthier Lives

diabetes-wordWashington, DC, November 17, 2016 — A new report released this week by the Pharmaceutical Research and Manufacturers of America’s (PhRMA) highlights continued progress and ongoing efforts in the research and development of new treatments for the more than 30 million Americans with diabetes and diabetes-related conditions.

According to the report — “Medicines in Development for Diabetes” — there are now more than 170 medicines in development for type 1 diabetes, type 2 diabetes and related diseases, such as chronic kidney disease.

The report highlights critical advancements in treatment that enable better adherence to medications and ultimately improved quality of health for patients. Continue reading

FDA Approves ‘Artificial Pancreas’ to Manage Diabetes

FDA approvedWashington, DC, October 4, 2016 — The Associated Press reports in The New York Times that the Food and Drug Administration (FDA) has approved a first-of-a-kind “artificial pancreas,” a device that can help some diabetes patients manage their disease by constantly monitoring their blood sugar and delivering insulin as needed.

The device from Medtronic was approved Wednesday for patients with Type 1 diabetes, the kind usually diagnosed during childhood. About 5 percent of the nation’s 29 million Americans with diabetes have this type.

Doctors said they have long awaited a device that could help patients around the clock. Continue reading

Stevens Institute Startup Offers Hope for Improved Diabetes Care Through Data

Stevens Institute of TechnologyHoboken, NJ, August 22, 2016 — It began with a conversation.

Justin Williams ’15, then a junior electrical engineering student at Stevens Institute of Technology, who was planning on a career in the defense industry, was talking with a friend diagnosed with diabetes about her daily routine of logging meals, monitoring blood sugar, taking medication — and about a hospital-paging device that had suddenly malfunctioned.

“I told her there had to be a better way,” he recalls, “and she just said, ‘you’re an engineer, why don’t you come up with something?’” Continue reading

WHO Calls for Global Action to Halt Rise in and Improve Care for People with Diabetes

WHOGeneva, Switzerland, April 9, 2016 ― The number of people living with diabetes has almost quadrupled since 1980 to 422 million adults, with most living in developing countries. Factors driving this dramatic rise include overweight and obesity, WHO announced ahead of World Health Day.

WHO is marking its annual World Health Day (7 April), which celebrates the Organization’s founding in 1948, by issuing a call for action on diabetes.  In its first “Global report on diabetes”, WHO highlights the need to step up prevention and treatment of the disease.

Health-Promoting Environments Reduce Risk Factors

Measures needed include expanding health-promoting environments to reduce diabetes risk factors, like physical inactivity and unhealthy diets, and strengthening national capacities to help people with diabetes receive the treatment and care they need to manage their conditions. Continue reading

Rutgers-Camden and Rowan Research Collaborate to Accelerate Fight Against Diabetes

Rutgers-Camden and Rowan UCamden, NJ, January 22, 2016 ― Researchers from Rutgers University–Camden and Rowan University are collaborating on an interdisciplinary project to accelerate the fight against diabetes and use untapped resources to improve treatment and perhaps even cure the disease.

The joint Rowan University/Rutgers–Camden Board of Governors approved a $30,000 research grant for the project.

“This valuable collaboration between South Jersey’s two most prominent universities has the real potential to change lives,” says Kris Kolluri, CEO of the Rowan University/Rutgers–Camden Board of Governors, an organization that promotes advancements in the life sciences in southern New Jersey.  Continue reading